sm 102

SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines.

244cis, an ionizable cationic lipid incorporating a piperazine structure, facilitates the creation of lipid nanoparticles (LNPs). These LNPs, when formulated with 244cis and coated with an mRNA reporter gene, exhibit preferential accumulation in the lungs of mice, in contrast to those formulated with SM-102. Additionally, it leads to a reduction in the levels of serum chemokine (C-C motif) ligand 2 (CCL2) [1].